This is a routine annual meeting proxy filing with no material new information for traders. Monitor for any dissident shareholder activity or unexpected vote outcomes around the June 18 meeting, but no immediate trading catalyst is present.
Price Chart
Executive Summary
Eupraxia Pharmaceuticals filed its management information circular and proxy materials for the upcoming annual general meeting on June 18, 2026. The filing is a routine governance document covering director elections, auditor appointment, and executive compensation disclosure. No material financial results, guidance, or operational catalysts were reported.
Key Facts
- Annual general meeting scheduled for June 18, 2026 in virtual-only format.
- Shareholders to vote on setting board size at seven, electing seven director nominees (including two new nominees Amy Pott and Robert Bazemore), and reappointing KPMG LLP as auditor.
- As of May 8, 2026 record date, there were 65,313,147 common shares outstanding.
- Mark Kowalski retired as Chief Medical Officer on May 1, 2026; Jeymi Tambiah assumed the role.
- CEO James Helliwell's 2025 total compensation was $4,535,622; CFO Alex Rothwell's was $5,436,566 (including a one-time RSU grant).
- The company's Omnibus Incentive Plan allows for a rolling maximum of 18.5% of outstanding shares for equity awards.
- No 10%+ beneficial holders were identified as of the record date.
Financial Impact
No material financial impact — routine proxy filing with no earnings, guidance, or operational data.
Risk Factors
- Low quorum requirement (5% of shares) could allow small shareholder groups to influence outcomes.
- No female directors on the board may raise governance concerns with some institutional investors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003787 |
| Exhibit: exh_992.htm | 0001171843-26-003787 |
| Exhibit: exh_993.htm | 0001171843-26-003787 |
| Document: f6k_052826.htm | 0001171843-26-003787 |
| Document: 0001171843-26-003787-index-headers.html | 0001171843-26-003787 |
| Document: 0001171843-26-003787-index.html | 0001171843-26-003787 |
| Document: 0001171843-26-003787.txt | 0001171843-26-003787 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $7.59 | awaiting T+5 | — | $6.85 (−9.75%) |
Oct 15, 2026 11d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $6.85 (+1.18%) |
Oct 9, 2026 17d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $6.85 (−8.18%) |
Sep 30, 2026 26d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Sep 30, 2026 26d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Aug 25, 2026 8w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $6.85 (+7.68%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $6.85 (+2.70%) |
Aug 11, 2026 10w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $6.85 (+5.71%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $6.85 (+5.06%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $6.85 (+3.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers